Viraemia and HIV drug resistance among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy-Reference-Cited by-同舟云学术

Viraemia and HIV drug resistance among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy

Published:2023-06-19 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Dorward Jienchi^ORCID,Sookrajh Yukteshwar^ORCID,Lessells Richard^ORCID,Bulo Elliot,Bodley Nicola,Singh Lavanya^ORCID,Moodley Pravikrishnen,Samsunder Natasha^ORCID,Drain Paul K.,Hayward Gail^ORCID,Butler Christopher C^ORCID,Garrett Nigel^ORCID

Abstract

SUMMARYLimited data exists to inform management of viraemia among people receiving dolutegravir-based first-line ART in low- and middle-income countries. Among South-Africans with viraemia ≥1000copies/mL receiving dolutegravir (n=43) and efavirenz (n=37), we found no dolutegravir resistance, but high efavirenz resistance (66.7%). 12-week resuppression was higher with dolutegravir (85%) versus efavirenz (38%).

Publisher

Cold Spring Harbor Laboratory

Reference12 articles.

1. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research

2. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries

3. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis

4. HIV drug resistance in low-income and middle-income countries

5. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study